Immediate Impact
2 from Science/Nature 50 standout
Citing Papers
Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study
2023 Standout
Pathophysiology, diagnosis, and management of endometriosis
2022 Standout
Works of E. Brand being referenced
Phase 3 Study: Canfosfamide (C, TLK286) plus carboplatin (P) vs liposomal doxorubicin (D) as 2nd line therapy of platinum (P) resistant ovarian cancer (OC)
2007
Malignancy arising in endometriosis associated with unopposed estrogen replacement.
1988
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| E. Brand | 85 | 118 | 124 | 23 | 361 | |
| DiSaia Pj | 73 | 142 | 143 | 21 | 345 | |
| Sanshiro Okamoto | 89 | 151 | 241 | 37 | 406 | |
| Sheila Segura | 75 | 117 | 158 | 33 | 304 | |
| Sergei Zehavi | 82 | 186 | 138 | 19 | 404 | |
| G Deppe | 176 | 179 | 103 | 27 | 384 | |
| S. Mancuso | 68 | 94 | 174 | 21 | 388 | |
| Samuel Ward | 120 | 47 | 114 | 15 | 322 | |
| Sherif Elsherif | 68 | 73 | 77 | 31 | 321 | |
| Xuelian Du | 90 | 126 | 187 | 22 | 362 | |
| Hiroshi Nanjyo | 90 | 138 | 152 | 28 | 377 |
All Works
Login with ORCID to disown or claim papers
Loading papers...